| 李珊珊 葛飞娇 王岩 林莉 徐建明.索拉非尼与舒尼替尼单药治疗晚期肝细胞癌的效果分析[J].,2014,14(7):1283-1286 |
| 索拉非尼与舒尼替尼单药治疗晚期肝细胞癌的效果分析 |
| Effects of Sorafenib or Sunitinib on the Treatment of the AdvancedHepatocellular Carcinoma |
| |
| DOI： |
| 中文关键词: 索拉非尼 舒尼替尼 肝细胞癌 治疗效果 不良反应 |
| 英文关键词: Sorafenib Sunitinib Advanced hepatocellular carcinoma Clinical effects Adverse reactions |
| 基金项目: |
|
| 摘要点击次数: 680 |
| 全文下载次数: 979 |
| 中文摘要: |
| 目的：对比索拉非尼(Sorafenib)和舒尼替尼(Sunitinib)单药治疗晚期肝细胞癌的疗效及安全性。方法：对我院2004 年1 月
-2010 年10 月收治的44 例晚期肝细胞肝癌患者的临床资料进行回顾分析。根据不同给药方式，将患者分为两组。其中，索拉非尼
组32 例患者采取口服索拉非尼进行治疗，而舒尼替尼组12例患者给予口服舒尼替尼治疗。观察并比较两组患者的治疗效果及
药物不良反应情况。结果：索拉非尼组总生存时间为6.3 月，1 年生存率为16%，肿瘤进展时间为3 个月，疾病控制率为71%；舒尼
替尼组总生存时间为4.7月，1 年生存率为8%，肿瘤进展时间为3 个月，疾病控制率为64%。两组临床效果差异无统计学意义
(P=0.2415，0.5706，0.7132)。索拉非尼组患者手足皮肤反应、中性粒细胞减少及肝损伤等主要毒副反应的发生率均低于舒尼替尼
组，差异具有统计学意义(P>0.05)。结论：索拉非尼治疗晚期肝细胞肝癌的临床效果与舒尼替尼具有很好的一致性，药物不良反应
相对较轻，患者依从性较好，值得临床推广应用。 |
| 英文摘要: |
| Objective:To observe the clinical efficacy of sorafenib and sunitinib on the treatment of the advanced hepatocellular
carcinoma, and to discuss the adverse reactions to patients.Methods: A retrospective analysis was performed on the clinical data of 44
patients with hepatocellular carcinoma who were treated in our hospital from January 2004 to October 2010. According to the different
medication modes, the patients were divided into two groups. Then the clinical effects and adverse reactions were observed and
compared between the two groups.Results:In the sorafenib group, the MOS was 6.3 months, the rate of one-year’s survival was 16%,
the MTTP was 3 months and the rate of disease control was 71%; In the sunitinib group, the MOS was 4.7 months, the rate of one-year’s
survival was 8%, the MTTP was 3 months and the rate of disease control was 64%. There was no statistically significant differences
about the clinical efficacy between the two groups (P=0.2415, 0.5706, 0.7132). The incidence of adverse reactions in the sorafenib group
was lower that that of the sunitinib group with statistically significant difference (P<0.05).Conclusion:It is indicated that the sorafenib
should be well promoted and make contribution to the treatment of the advanced hepatocellular carcinoma with the advantage of high
consistency in accuracy and safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
